SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Charles Darwin Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientCharles Darwin
Date of birth1809-02-12
IdentifiersMRN HR-NI003-SYN-TD; SSN (made up) 000-03-2967
Document date2026-11-01
AuthorBernard Ashworth, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Evaluation of recurrent vomiting episodes: history, symptom diary, Rome IV criteria, red flags, cannabis and substance history, anxiety and mood screens, laboratory tests, ECG, and orders for small-bowel imaging and upper endoscopy. Concerns: For more than a year he has had episodes of nausea and repeated vomiting every one to three weeks, each lasting about 12 to 36 hours, that stop his work; this winter they came almost every week; Each episode begins with nausea, sweating, trembling hands, a racing heart, and a swimming head; between episodes he has troublesome wind and tires easily, but does not vomit; He worries about being taken ill in company and has begun to avoid gatherings and travel. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amitriptyline 25 mg oral tablet, one tablet at bedtimeOne tablet by mouth at bedtimeOral route1849-04-14 to 1849-04-28completedS
Amitriptyline 50 mg oral tablet, one tablet at bedtimeOne tablet by mouth at bedtimeOral route1849-04-28 to 1849-05-12completedS
Amitriptyline 75 mg oral tablet, one tablet at bedtimeOne tablet by mouth at bedtimeOral route1849-05-12activeS
Sumatriptan 20 mg nasal spray, one spray at the first sign of an episodeOne spray in one nostril at the start of the prodrome; may repeat once after 2 hours; no more than 2 sprays a day or 6 a weekNasal route1849-04-14activeS
Ondansetron 8 mg orally disintegrating tablet at the first sign of an episodeDissolve one tablet on the tongue at the start of the prodrome, then every 8 hours as needed during an episodeOral route1849-04-14activeS

Procedures

ProcedureDatesStatusEvidence
CT enterography (CT of the small bowel with oral and intravenous contrast): normal small and large bowel, no obstruction, malrotation, stricture, or wall thickening; normal liver, gallbladder, pancreas, and kidneys1849-03-17 to 1849-03-17completedS
Upper endoscopy (esophagogastroduodenoscopy) with duodenal biopsies: normal esophagus, stomach, and duodenum; no ulcer, obstruction, or retained food; duodenal biopsies normal1849-03-31 to 1849-03-31completedS

Immunizations

DateVaccineStatusEvidence
1848-10-14Influenza vaccine, 1848-1849 seasoncompletedS
1842-06-11Tetanus, diphtheria, and acellular pertussis (Tdap) boostercompletedS
1849-07-21Hepatitis B vaccine (adjuvanted, two-dose series), dose 1completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
December 1831Palpitations and pain about the heart while waiting to sail on the Beagle; no doctor consultedD (CLM-0003)
September 1837Palpitations, treated with rest in the country on his doctors' adviceD (CLM-0004)
June 1840Periodical vomiting, first mentioned in a letter; cause not recorded in the cited sourceD (CLM-0005)
February 1849A winter of dreadful vomiting every week, with trembling hands and a swimming head, and incessant vomiting described in a letter; cause not recorded in the cited sourceD (CLM-0006)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
For more than a year he has had episodes of nausea and repeated vomiting every one to three weeks, each lasting about 12 to 36 hours, that stop his work; this winter they came almost every weekactiveS
Each episode begins with nausea, sweating, trembling hands, a racing heart, and a swimming head; between episodes he has troublesome wind and tires easily, but does not vomitactiveS
He worries about being taken ill in company and has begun to avoid gatherings and travelactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 14.6 on 1849-03-03; Leukocytes [#/volume] in Blood by Automated count 6.4 on 1849-03-03; Platelets [#/volume] in Blood by Automated count 251 on 1849-03-03; Sodium [Moles/volume] in Serum or Plasma 140 on 1849-03-03; Potassium [Moles/volume] in Serum or Plasma 4.1 on 1849-03-03; Chloride [Moles/volume] in Serum or Plasma 103 on 1849-03-03; Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 on 1849-03-03; Creatinine [Mass/volume] in Serum or Plasma 0.94 on 1849-03-03; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1844)/1.73 sq M 104 on 1849-03-03; Glucose [Mass/volume] in Serum or Plasma 88 on 1849-03-03; Calcium [Mass/volume] in Serum or Plasma 9.5 on 1849-03-03; Albumin [Mass/volume] in Serum or Plasma 4.4 on 1849-03-03; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 on 1849-03-03; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 19 on 1849-03-03; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 68 on 1849-03-03; Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 on 1849-03-03; Lipase [Enzymatic activity/volume] in Serum or Plasma 32 on 1849-03-03; Thyrotropin [Units/volume] in Serum or Plasma 1.6 on 1849-03-03; Cortisol [Mass/volume] in Serum or Plasma 14.2 on 1849-03-03; Tissue transglutaminase IgA Ab [Units/volume] in Serum 1.2 on 1849-03-03; IgA [Mass/volume] in Serum or Plasma 210 on 1849-03-03; Q-T interval corrected 436 on 1849-06-09; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 5 on 1849-09-08; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 1849-09-08; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1849-07-21; Total score [AUDIT-C] 2 on 1849-07-21; Cholesterol [Mass/volume] in Serum or Plasma 178 on 1849-07-21; Cholesterol in HDL [Mass/volume] in Serum or Plasma 58 on 1849-07-21; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 102 on 1849-07-21; Triglyceride [Mass/volume] in Serum or Plasma 90 on 1849-07-21 [S]

Strengths and supports: Supports: a settled household, absorbing scientific work, daily walks, and a habit of keeping careful notes that suits a symptom diary [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Cyclic vomiting syndrome, moderate to severe, meeting Rome IV criteria after a normal work-up; provisional clinical diagnosisactiveprovisional R11.15S — Synthetic provisional diagnosis at the gastroenterology consultation, anchored to his documented episodic vomiting. It is clinical, with no confirmatory test, and does not confirm any historical theory.
Recurrent episodes of nausea and vomiting over more than a year, with prodromal trembling, palpitations, and dizziness, and flatulence and fatigue between episodes; cause under evaluationresolvedconfirmed R11.2S — Synthetic presenting concern at the index visit, superseded by the provisional diagnosis at the six-week visit; the episodic vomiting is documented (D).
Common cold, without a vomiting episode; resolvedresolvedconfirmed J00S — Synthetic intercurrent illness at an unscheduled visit; chosen because infection is a common trigger of cyclic vomiting and because cold medicines interact with amitriptyline. It does not echo a documented illness.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1849-03-03Hemoglobin [Mass/volume] in Blood14.6g/dL13.2-16.6 g/dLNormalS
1849-03-03Leukocytes [#/volume] in Blood by Automated count6.410*3/uL3.4-9.6 10*3/uLNormalS
1849-03-03Platelets [#/volume] in Blood by Automated count25110*3/uL135-317 10*3/uLNormalS
1849-03-03Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1849-03-03Potassium [Moles/volume] in Serum or Plasma4.1mmol/L3.5-5.1 mmol/LNormalS
1849-03-03Chloride [Moles/volume] in Serum or Plasma103mmol/L98-107 mmol/LNormalS
1849-03-03Carbon dioxide, total [Moles/volume] in Serum or Plasma25mmol/L22-29 mmol/LNormalS
1849-03-03Creatinine [Mass/volume] in Serum or Plasma0.94mg/dL0.74-1.35 mg/dLNormalS
1849-03-03Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1844)/1.73 sq M104mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1849-03-03Glucose [Mass/volume] in Serum or Plasma88mg/dL70-99 mg/dLNormalS
1849-03-03Calcium [Mass/volume] in Serum or Plasma9.5mg/dL8.6-10.3 mg/dLNormalS
1849-03-03Albumin [Mass/volume] in Serum or Plasma4.4g/dL3.5-5 g/dLNormalS
1849-03-03Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L7-55 U/LNormalS
1849-03-03Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L8-48 U/LNormalS
1849-03-03Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma68U/L40-129 U/LNormalS
1849-03-03Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.1-1.2 mg/dLNormalS
1849-03-03Lipase [Enzymatic activity/volume] in Serum or Plasma32U/L13-60 U/LNormalS
1849-03-03Thyrotropin [Units/volume] in Serum or Plasma1.6m[IU]/L0.45-4.5 mIU/LNormalS
1849-03-03Cortisol [Mass/volume] in Serum or Plasma14.2ug/dL6.2-19.4 ug/dLNormalS
1849-03-03Tissue transglutaminase IgA Ab [Units/volume] in Serum1.2U/mL<=3.9 U/mLNormalS
1849-03-03IgA [Mass/volume] in Serum or Plasma210mg/dL70-400 mg/dLNormalS
1849-03-03Q-T interval corrected412ms<=450 msNormalS
1849-06-09Q-T interval corrected436ms<=450 msNormalS
1849-03-03Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]8{score}S
1849-03-03Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
1849-06-09Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]6{score}S
1849-06-09Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
1849-09-08Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]5{score}S
1849-09-08Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
1849-07-21Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1849-07-21Total score [AUDIT-C]2{score}S
1849-07-21Cholesterol [Mass/volume] in Serum or Plasma178mg/dL<=200 mg/dLNormalS
1849-07-21Cholesterol in HDL [Mass/volume] in Serum or Plasma58mg/dL>=40 mg/dLNormalS
1849-07-21Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation102mg/dL<=129 mg/dLNormalS
1849-07-21Triglyceride [Mass/volume] in Serum or Plasma90mg/dL<=149 mg/dLNormalS

Social History

Vital Signs

DateMeasureValueUnitProvenance
1849-03-03Body height183cmS
1849-03-03Body weight71.6kgS
1849-03-03Body mass index (BMI) [Ratio]21.4kg/m2S
1849-03-03Systolic blood pressure118mm[Hg]S
1849-03-03Diastolic blood pressure74mm[Hg]S
1849-03-03Heart rate78/minS
1849-03-03Respiratory rate14/minS
1849-03-03Body temperature36.6CelS
1849-03-03Oxygen saturation in Arterial blood by Pulse oximetry99%S
1849-04-14Body height183cmS
1849-04-14Body weight71.4kgS
1849-04-14Body mass index (BMI) [Ratio]21.3kg/m2S
1849-04-14Systolic blood pressure116mm[Hg]S
1849-04-14Diastolic blood pressure72mm[Hg]S
1849-04-14Heart rate76/minS
1849-04-14Respiratory rate14/minS
1849-04-14Body temperature36.7CelS
1849-04-14Oxygen saturation in Arterial blood by Pulse oximetry99%S
1849-06-09Body height183cmS
1849-06-09Body weight72.4kgS
1849-06-09Body mass index (BMI) [Ratio]21.6kg/m2S
1849-06-09Systolic blood pressure118mm[Hg]S
1849-06-09Diastolic blood pressure74mm[Hg]S
1849-06-09Heart rate72/minS
1849-06-09Respiratory rate14/minS
1849-06-09Body temperature36.6CelS
1849-06-09Oxygen saturation in Arterial blood by Pulse oximetry99%S
1849-09-08Body height183cmS
1849-09-08Body weight72.9kgS
1849-09-08Body mass index (BMI) [Ratio]21.8kg/m2S
1849-09-08Systolic blood pressure116mm[Hg]S
1849-09-08Diastolic blood pressure72mm[Hg]S
1849-09-08Heart rate70/minS
1849-09-08Respiratory rate14/minS
1849-09-08Body temperature36.6CelS
1849-09-08Oxygen saturation in Arterial blood by Pulse oximetry99%S
1849-05-19Body height183cmS
1849-05-19Body weight72.1kgS
1849-05-19Body mass index (BMI) [Ratio]21.5kg/m2S
1849-05-19Systolic blood pressure118mm[Hg]S
1849-05-19Diastolic blood pressure72mm[Hg]S
1849-05-19Heart rate84/minS
1849-05-19Respiratory rate16/minS
1849-05-19Body temperature37.8CelS
1849-05-19Oxygen saturation in Arterial blood by Pulse oximetry98%S
1849-07-21Body height183cmS
1849-07-21Body weight72.6kgS
1849-07-21Body mass index (BMI) [Ratio]21.7kg/m2S
1849-07-21Systolic blood pressure116mm[Hg]S
1849-07-21Diastolic blood pressure72mm[Hg]S
1849-07-21Heart rate70/minS
1849-07-21Respiratory rate14/minS
1849-07-21Body temperature36.6CelS
1849-07-21Oxygen saturation in Arterial blood by Pulse oximetry99%S

Encounters

DatePurposeStatusProvenance
1849-03-03Evaluation of recurrent vomiting episodes: history, symptom diary, Rome IV criteria, red flags, cannabis and substance history, anxiety and mood screens, laboratory tests, ECG, and orders for small-bowel imaging and upper endoscopyfinishedS
1849-04-14Six-week follow-up: results, gastroenterology consultation, provisional diagnosis, prophylaxis, and abortive planfinishedS
1849-06-09Three-month review: amitriptyline at target dose, ECG, episode diary, and anxiety screenfinishedS
1849-09-08Six-month review of response to prophylaxisfinishedS
1849-05-19Same-day sick visit for a head coldfinishedS
1849-07-21Preventive health visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Work-up between episodes: blood count, metabolic and liver panels, lipase, urinalysis, TSH, morning cortisol, celiac serology, a baseline ECG, CT enterography, and upper endoscopycompletedGL-ANMS-CVS-2019S
Gastroenterology consultation to confirm the diagnosis and advise on prophylaxis, abortive treatment, and an emergency plancompletedGL-ANMS-CVS-2019S
Symptom diary: date, prodrome, length and severity of each episode, triggers, medicines taken, and emergency visitscompletedGL-ANMS-CVS-2019S
Amitriptyline prophylaxis at bedtime: 25 mg, raised by 25 mg every two weeks to 75 mg (about 1 mg/kg), with an ECG at baseline, at about 50 mg, and at the target dose; judge the response after three months at target and continue for at least a year if it helpscompletedGL-ANMS-CVS-2019S
Abortive plan at the first sign of the prodrome: sumatriptan 20 mg nasal spray with ondansetron 8 mg dissolving tablet, a dark quiet room, and small sips of fluid; an individualized emergency department letter for episodes that do not settlecompletedGL-ANMS-CVS-2019S
Trigger management: regular meals and sleep, planning around travel and social events, early treatment of infections, and continued avoidance of cannabiscompletedGL-ANMS-CVS-2019S
Anxiety and mood: GAD-7 and PHQ-9 at the first visit and every three months; relaxation breathing, with cognitive behavioral therapy offered if symptoms persistcompletedGL-ANMS-CVS-2019, GL-USPSTF-ANX-2023S

Goals

GoalTargetStatusOutcomeProvenance
Complete the work-up between episodes (blood and urine tests, ECG, CT enterography, and upper endoscopy) before the six-week visit1849-04-14completedAll tests normal; Rome IV criteria met; provisional diagnosis of cyclic vomiting syndrome at the consultationS
At least half as many episodes after three months at the target dose of prophylaxis1849-09-08completedAbout two episodes a month before treatment; one brief episode, aborted at the prodrome, in the three months before the six-month reviewS
Carry the abortive medicines and the emergency department letter, and use them at the prodrome1849-06-09completedThe one episode since starting treatment was treated at the prodrome and settled in about ten hours without an emergency visit; letter carriedS
QTc below 450 ms at the target amitriptyline dose1849-06-09completedQTc 436 ms on 75 mgS
Practice relaxation breathing most days and lower the GAD-7 score by the six-month review1849-09-08completedDaily breathing practice; GAD-7 from 8 to 5S

Functional Status

Mental Status